Atenolol is a type of beta-blocker drug that is used to treat a variety of illnesses. Atenolol Manufacturers make the drug to treat excessive blood pressure and irregular heartbeats, as well as to avoid chest pain caused by angina. It's sometimes recommended to aid with anxiety and migraine prevention. Atenolol can also help prevent strokes, heart attacks, and heart disease in the future. Atenolol was first invented in 1969 and was licensed for medicinal use in 1975. It is available as a tablet or as a liquid that can be swallowed. According to the World Health Organization, high blood pressure is responsible for around 7.5 million fatalities per year. As a result, atenolol producers and suppliers will have their hands full ensuring a steady supply of the medication on the global market. Tenormin, Tenif, and Co-tenidone are just a few of the brand names for atenolol, which is a beta-blocker. Atenolol works by inhibiting the heart's 1-adrenergic receptors. This lowers the heart rate, making it considerably easier to circulate blood throughout the body. Sleepiness, dizziness, and constipation are some of the major adverse effects of atenolol that some patients experience. Many people experience no side effects or very minimal ones. Patients' doses vary according to their needs, but for high blood pressure, a normal dose is 25mg to 50mg administered once a day.

Atenolol is a sympathomimetic beta-blocker, meaning it interacts to the cause possible harm receptor as antagonists up to 26 times more than the 2-adrenergic receptor. Due to the greater density of these receptors in heart cells, selective action at the 1 receptors provides cardioselectivity. At therapeutic doses, some interaction to 2 and potentially 3 transmitters can still occur, but the effects mediated by antagonizing these channels are greatly diminished compared to non-selective drugs. Because adenylyl synthase and its upstream signaling via cyclical adenosine inorganic phosphate and protein kinase A are Gs linked, antagonizing their activation lowers adenylyl cyclase function and its down transmission via cyclic adenosine inorganic phosphate and phosphorylates A. PKA is hypothesized to activate L-type calcium channels and ryanodine receptors in cardiomyocytes by phosphorylating them. The adrenergic receptors are then triggered to release calcium stashed in the sarcoplasm (SR), resulting in increased contractility. 16 L-type calcium ions can then provide an initial rise in cytosolic ca2, triggering the ryanodine receptor sites to release calcium stored in the sarcoplasmic reticulum (SR). PKA also helps to stop contractions by phosphorylating phospholamban, which improves the affinity of SR Ca2+ ATPase, which improves ca absorption into the SR. Troponin I is also phosphorylated, which reduces the protein's attraction for calcium. Both of these occurrences cause a contraction decrease, which, when combined with the original contractions increase, leads to faster cyclists and, as a result, a greater heart rate with enhanced contractility. The activation of L-type calcium channels, which contribute to cardiac polarization, might increase the frequency of nerve impulses and possibly the occurrence of ectopic possibilities. Inhibitory events such as stimulation of myosin light-chain kinase, which reduces myosin light-chain kinase's sensitivity for calcium, happen in the bronchial smooth muscle to control relaxation. PKA also suppresses the excitable Gq linked channel by phosphorylating the oligosaccharide trisphosphate transporter and phosphatases C, which causes calcium ions release to be inhibited. Beta-blocker drugs like atenolol can disrupt this activity, resulting in greater respiratory distress.

Atenolol's wholesale price in the United States in 2018 was less than $15 per month, and it was the country's 20th most prescribed drug two years ago. A month of treatment in the United Kingdom costs less than £5. After receiving the drug, keep it in the original container and store it at room temperature away from heat and moisture.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Atenolol offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for Atenolol manufacturers and Atenolol suppliers that you are looking for. These also enable you to check the dossier status of Atenolol and the GMP approvals of the different variants of Atenolol. Also, each manufacturer or supplier product description contains essential information about Atenolol including clinical data, stability zones, countries where Atenolol is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Atenolol offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that Atenolol manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Atenolol manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.